Inhibikase Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
14/05/2025 21:09
Inhibikase Therapeutics Inc IKT.OQ IKT.O is expected to show no change in quarterly revenue when it reports results on May 16 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Inhibikase Therapeutics Inc is for a loss of 10 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is $8.00, above its last closing price of $2.23. This summary was machine generated May 14 at 20:09 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary